KLIFO Publishes 2024 Annual Report: Strategic Investments and Continued Growth in Drug Development Consultancy and Clinical Trial Supply

Glostrup, Denmark – KLIFO, the leading integrated Drug Development Consultancy and Clinical Trial Supply, has released its Annual Report for the financial year ending 31 December 2024. Despite operating in a persistently challenging biotech funding environment, KLIFO has delivered resilient performance and made major strategic investments to position the company for long-term growth.

Strategic Progress and Financial Highlights:

The company reported a positive EBITDA* for the group of DKK 4.9 million, including accelerated investments and transformation initiatives. The equity furthermore increased to DKK 79.1 million, including a capital contribution to fund strategic growth investments.

KLIFO has historically operated across three core business areas: Clinical Trial Supply, Drug Development Consultancy, and Full-Service CRO. In recent years, the company has seen sustained growth and stability in both Clinical Trials Supply and Drug Development Consultancy and we continue to scale in 2025 to support an increasing order book.

Notable milestones from 2024 include:

• Expansion of Clinical Trial Supply capabilities: In response to growing demand, KLIFO is launching a new state-of-the-art Clinical Trial Supply facility in the Copenhagen area, set to open in 2025. The new facility will quadruple our capacity, making it the largest of its kind in Northern Europe.
• Growth in Advisory services: KLIFO continues to scale its high-value Advisory business, recruiting senior specialists across all areas; Drug Development Consulting, Regulatory Affairs, CMC, and Quality Assurance.
• Strategic transformation: KLIFO is continuing its strategic ambition of expanding
  within premium Clinical Development consulting focusing on delivering deeper expertise and tailored guidance, while lowering the exposure from the full-service CRO offerings especially in the Nordics.
• Looking ahead: As part of its forward-looking growth strategy, KLIFO is actively
  exploring M&A opportunities and strategic partnerships, aimed at expanding
  capabilities and accelerating innovation for clients globally.

“Despite market headwinds, 2024 was a year of decisive action and bold investment. With our strategic transformation well underway and demand in our core areas stronger than ever, we are confident in KLIFO’s growth trajectory for 2025 and beyond,” said René Pedersen, CEO of KLIFO (acting).

The full Annual Reports for 2024 is available on CVR.dk.

*) EBITDA equals Profit before net financials adjusted for depreciation and amortization.